TD Cowen analyst Josh Jennings maintained a Buy rating on TransMedics Group yesterday and set a price target of $170.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight TransMedics Group’s strong market position and growth potential. The recent acquisition of OrganOx by Terumo has underscored the importance of machine perfusion in organ transplantation, which aligns with TransMedics’ strategic focus. Jennings believes that this acquisition validates the potential of TransMedics’ OCS platform and indicates that the company is currently undervalued by the market.
TransMedics’ OCS system boasts significant competitive advantages, particularly in terms of mobility and clinical outcomes. The system’s portability has resulted in a high utilization rate, which is unmatched in the industry, and its low complication rates further strengthen its market position. These factors collectively contribute to Jennings’s confidence in the company’s ability to capitalize on the growing market opportunity and maintain its leadership in the organ transplant sector.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $130.00 price target.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.